In addition, the authors reported that ruxolitinib is superior compared to the best available therapy (including interferon) in terms of achieving haematocrit control, spleen response, complete haematological remission, and overall clinico-haematological response.1

Polycythaemia vera is a rare, chronic disorder defined as a myeloproliferative neoplastic disorder involving uncontrolled red blood cell production

Please sign in to read more